SIRONAX
Sironax is a clinical-stage biotechnology company that develops novel products and treatments for age-related degenerative diseases. The company is focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. They aim to shift the treatment paradigm for age-related degenerative disease to improve the lives of millions of patients and their families around the world. Sironax was founded in 2017 and is based in Beijing, China.
SIRONAX
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2017-09-01
Address:
Beijing, Beijing, China
Country:
China
Website Url:
http://www.sironax.com.cn
Total Employee:
101+
Status:
Active
Contact:
86-10-80765868
Email Addresses:
[email protected]
Total Funding:
301 M USD
Technology used in webpage:
IPv6
Current Employees Featured
Founder
Investors List
Temasek Holdings
Temasek Holdings investment in Series B - Sironax
Future Innovation Fund
Future Innovation Fund investment in Series B - Sironax
Eight Roads Ventures
Eight Roads Ventures investment in Series B - Sironax
Superstring Capital
Superstring Capital investment in Series B - Sironax
F-Prime Capital
F-Prime Capital investment in Series B - Sironax
YF Capital
YF Capital investment in Series B - Sironax
Invus
Invus investment in Series B - Sironax
CBC Group
CBC Group investment in Series B - Sironax
K2 Venture Capital
K2 Venture Capital investment in Series B - Sironax
Gaorong Capital
Gaorong Capital investment in Series B - Sironax
Official Site Inspections
http://www.sironax.com.cn
- Host name: 156.225.111.19
- IP address: 156.225.111.19
- Location: Johannesburg South Africa
- Latitude: -26.2309
- Longitude: 28.0583
- Timezone: Africa/Johannesburg
- Postal: 2000
More informations about "Sironax"
维泰瑞隆（北京）生物科技有限公司 - SIRONAX
Aug 2, 2022 维泰瑞隆,sironax,北京维泰瑞隆,生物科技有限公司,退行性疾病,退行性神经疾病,老年痴呆,变革性疗法See details»
SIRONAX
Sironax is currently conducting early clinical studies with SIR2446 and SIR9900, in addition to ongoing preclinical research. more. company news. Aug 02, 2022. Sironax Announces Closing …See details»
Sironax - Crunchbase Company Profile & Funding
Sironax is a clinical-stage biotechnology company that develops novel products and treatments for age-related degenerative diseases. The company is focusing on key mechanisms …See details»
SIRONAX
Sironax is an emerging leader in the discovery and development of transformational therapies that address the root cause of age-related degenerative disease. Today, the majority of treatments …See details»
Sironax Company Profile | Management and Employees List
Sironax headquarters are located in 8-10/f Building 2 Medical Technology Center Zhongguancun Life Science Park Changping District, Beijing, Beijing, 102206, China . What are Sironax’s …See details»
Sironax - LinkedIn
Sironax is currently conducting early clinical studies with SIR0365 and SIR2446, in addition to ongoing preclinical research. ... Beijing 100000, CN Get directions 86 Jianguo Road Room 2302, FL23 ...See details»
Sironax Company Profile - Office Locations, Competitors ... - Craft
Sironax (维泰瑞隆) is a biotechnology company dedicated to the discovery and global development of new treatments for patients with age-related degenerative diseases. It …See details»
Sironax Company Profile 2024: Valuation, Funding & Investors
Sironax General Information Description. Developer and researcher of pharmaceuticals for inflammatory and neurodegenerative diseases. The company researches apoptosis and other …See details»
Sironax - Company Profile - Tracxn
Nov 5, 2024 Sironax ranks 107th among 423 active competitors. 152 of its competitors are funded while 73 have exited. Overall, Sironax and its competitors have raised over $10.6B in …See details»
Sironax CEO and Key Executive Team | Craft.co
Sironax's Chief Executive Officer, Director is Aaron Ren. Other executives include Xiaodong Wang, Chairman & Co-Founder; Jian Cui, SVP of CMC and 11 others. ... Source: …See details»
Sironax - Overview, News & Similar companies | ZoomInfo.com
Jan 4, 2023 China-based Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related …See details»
About Us - sironax.com.cn
维泰瑞隆,sironax,北京维泰瑞隆,生物科技有限公司,退行性疾病,退行性神经疾病,老年痴呆,变革性疗法See details»
王晓东博士联合创立！维泰瑞隆首款新药在中国获批临床
中国国家药监局药品审评中心(CDE)最新公示，维泰瑞隆(北京)生物科技有限公司(Sironax，下称维泰瑞隆)申报的1类新药SIR1-365片，已获得临床试验默示许可，拟开发用于：治疗与全身性炎 …See details»
Sironax Announces Closing of $200 Million Series B Financing
Beijing, August 2, 2022 – Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related …See details»
SIR5 - Drug Targets, Indications, Patents - Synapse
SIR5, Initially developed by Sironax Ltd., Now, its global highest R&D status is Discovery, Therapeutic Areas: Nervous System Diseases, Active Indication: Neurodegenerative …See details»
Sironax Announces Closing of $200 Million Series B Financing - PR …
Aug 2, 2022 Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases. …See details»
SIRONAX
Mike (Xuesong) Liu, Ph.D. SVP of Portfolio Management. Yanping Xu, Ph.D. SVP of R&D. Libin Shang, Ph.D. VP of BD and PASee details»
Chinese biotech Sironax raises $200m for RIPK1 pipeline
Aug 3, 2022 Sironax' lead RIPK1 drug, SIR0365, has completed two phase 1b studies including one looking at its potential as a treatment for severe hyperinflammation associated with …See details»
志在FIC：王晓东/张志远博士公司Sironax国内首次递交IND，RIPK1 …
Jul 28, 2021 2018年，北生所（NIBS）所长王晓东院士和原北生所资深研究员张志远博士正式共同创建维泰瑞隆（Sironax），目标是做一家全球性的专注于研发First-in-class化学药物的生物 …See details»
Innovation - SIRONAX
维泰瑞隆,sironax,北京维泰瑞隆,生物科技有限公司,退行性疾病,退行性神经疾病,老年痴呆,变革性疗法See details»